SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression - PR Newswire

Submitted by Anonymous (not verified) on Tue, 01/21/2025 - 13:00

SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression  PR Newswire